Gary W Small Selected Research

dicyanmethane (malononitrile)

1/2016	Modifiable Risk Factors and Brain Positron Emission Tomography Measures of Amyloid and Tau in Nondemented Adults with Memory Complaints.
1/2013	Vascular risk and FDDNP-PET influence cognitive performance.
7/2012	Self-reported memory impairment and brain PET of amyloid and tau in middle-aged and older adults without dementia.
2/2012	Prediction of cognitive decline by positron emission tomography of brain amyloid and tau.
11/2011	Protein binding in patients with late-life depression.
6/2011	Positron emission tomography of brain β-amyloid and τ levels in adults with Down syndrome.
1/2011	The merits of FDDNP-PET imaging in Alzheimer's disease.
3/2010	PET of brain prion protein amyloid in Gerstmann-Sträussler-Scheinker disease.
2/2010	Movement correction method for human brain PET images: application to quantitative analysis of dynamic 18F-FDDNP scans.
6/2009	Depression and anxiety symptoms are associated with cerebral FDDNP-PET binding in middle-aged and older nondemented adults.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Gary W Small Research Topics

Disease

36	Alzheimer Disease (Alzheimer's Disease) 01/2018 - 01/2002
14	Cognitive Dysfunction 04/2017 - 07/2002
12	Amyloid Plaque 01/2019 - 01/2002
11	Dementia (Dementias) 01/2018 - 06/2003
6	Memory Disorders (Memory Loss) 01/2021 - 08/2002
4	Disease Progression 01/2013 - 01/2005
3	Parkinson Disease (Parkinson's Disease) 01/2013 - 05/2003
2	Chronic Traumatic Encephalopathy 01/2018 - 10/2016
2	Down Syndrome (Down's Syndrome) 01/2017 - 06/2011
2	Tauopathies 01/2013 - 01/2011
2	Frontotemporal Dementia (Semantic Dementia) 02/2008 - 11/2006
1	Schizophrenia (Dementia Praecox) 01/2020
1	Brain Concussion (Cerebral Concussion) 02/2013
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2013
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2013
1	Progressive Supranuclear Palsy (Steele Richardson Olszewski Syndrome) 01/2013
1	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2013
1	Stroke (Strokes) 01/2013
1	Major Depressive Disorder (Major Depressive Disorders) 11/2011
1	Atrophy 01/2011
1	Brain Diseases (Brain Disorder) 03/2010
1	Drug-Related Side Effects and Adverse Reactions 01/2010
1	Mixed Dementias 06/2003
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 06/2003
1	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy) 06/2003
1	Parkinsonian Disorders (Parkinsonism) 05/2003

Drug/Important Bio-Agent (IBA)

21	Amyloid (Amyloid Fibrils)IBA 01/2019 - 05/2005
15	dicyanmethane (malononitrile)IBA 01/2016 - 01/2002
8	2- (1- (6- ((2- fluoroethyl)(methyl)amino)- 2- naphthyl)ethylidene)malononitrileIBA 01/2019 - 01/2002
7	Biomarkers (Surrogate Marker)IBA 01/2018 - 08/2002
7	Apolipoproteins E (ApoE)IBA 01/2018 - 01/2002
5	ApolipoproteinsIBA 01/2018 - 11/2010
5	FluorineIBA 02/2012 - 05/2009
5	Glucose (Dextrose)FDA LinkGeneric 07/2009 - 07/2002
4	Amyloid beta-PeptidesIBA 01/2006 - 01/2002
3	Apolipoprotein E4IBA 01/2009 - 12/2002
2	HomocysteineIBA 04/2017 - 01/2016
2	2- (1,1- dicyanopropenyl- 2- )- 6- dimethylaminonaphthaleneyIBA 11/2003 - 01/2002
2	Cholinesterase Inhibitors (Anticholinesterases)IBA 06/2003 - 01/2002
1	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2021
1	Antipsychotic Agents (Antipsychotics)IBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 01/2017
1	tau Proteins (tau Protein)IBA 02/2013
1	RNA (Ribonucleic Acid)IBA 01/2013
1	AntioxidantsIBA 01/2013
1	Protein Isoforms (Isoforms)IBA 01/2013
1	Amyloidogenic ProteinsIBA 11/2011
1	Prion ProteinsIBA 03/2010
1	PrionsIBA 03/2010
1	Molecular Probes (Molecular Probe)IBA 07/2009
1	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 12/2008
1	Celecoxib (Celebrex)FDA Link 12/2008
1	VaccinesIBA 02/2008
1	Neurotransmitter Agents (Neurotransmitter)IBA 02/2008
1	benzamideIBA 01/2006
1	Serotonin (5 Hydroxytryptamine)IBA 01/2006
1	5-HT1A Serotonin ReceptorIBA 01/2006
1	naphthaleneIBA 01/2006
1	Peptides (Polypeptides)IBA 05/2005
1	Rivastigmine (Exelon)FDA LinkGeneric 01/2005
1	Mitochondrial DNA (mtDNA)IBA 07/2004
1	Glutathione Transferase (Glutathione S-Transferase)IBA 12/2003
1	Non-Steroidal Anti-Inflammatory Agents (NSAIDs)IBA 11/2003
1	Ibuprofen (Motrin)FDA LinkGeneric 11/2003
1	Naproxen (Naprosyn)FDA LinkGeneric 11/2003
1	NaphthalenesIBA 11/2003
1	Galantamine (Galanthamine)FDA LinkGeneric 06/2003
1	Ubiquitin-Protein Ligases (Ubiquitin-Protein Ligase)IBA 05/2003

Therapy/Procedure

2	Cognitive Training 01/2018 - 06/2012
2	Therapeutics 01/2013 - 01/2010
2	Intravenous Injections 06/2009 - 01/2009
1	Patient Readmission 01/2020
1	Injections 01/2020